This first in‑human biodistribution and imaging study for 68Ga‑EMP‑100 in metastatic renal cell carcinoma independently carried out by LMU Munich, Germany, evaluated uptake characteristics in metastases and primary RCC.
Conclusion: Visualization of c-MET expression with 68Ga-EMP-100 PET imaging allows for clinicopathological staging in mRCC and has potential as a predictive biomarker of targeted therapies.
